Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma

• Published in: International journal of particle therapy Vol. 2; no. 4; pp. 533 - 543
• Main Authors: Holliday, Emma, Bhattasali, Onita, Kies, Merrill S, Hanna, Ehab, Garden, Adam S, Rosenthal, David I, Morrison, William H, Gunn, G Brandon, Phan, Jack, Zhu, X Ronald, Zhang, Xiaodong, Frank, Steven J
• Format: Journal Article
• Language: English
• Published: United States The Particle Therapy Co-operative Group 01.03.2016
• Subjects: Original; head and neck neoplasms; proton radiotherapy; robust planning; adenoid cystic carcinoma; intensity-modulated proton therapy
• ISSN: 2331-5180; 2331-5180
• DOI: 10.14338/IJPT-15-00032.1

Postoperative radiation therapy can improve control for adenoid cystic carcinoma (ACC) of the head and neck; however, delivering adequate dose to the tumor bed must be balanced with limiting dose to nearby critical organs. Intensity-modulated proton therapy (IMPT) may help improve the therapeutic ratio, though concerns exist regarding tissue heterogeneity and other sources of uncertainty in several head and neck subsites. We report control and toxicity outcomes for patients with ACC of the head and neck treated at a single institution with postoperative IMPT and robust planning and analysis. Sixteen patients with head and neck ACC treated with postoperative IMPT were identified. Intensity-modulated proton therapy was delivered by using multifield optimization. Robust planning and analysis were performed. The median dose was 60 (range, 60 to 70) Gy (RBE) (Gy [relative biological effectiveness]). Adjuvant IMPT was given with (N = 12) or without (N = 4) platinum-based chemotherapy. Tumor control outcomes were recorded from the medical record, and acute and chronic toxicities were graded weekly during treatment and upon follow-up per Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4). Median follow-up is 24.9 (range, 9.2 to 40.2) months. One patient developed local and distant recurrence and subsequently died. The remaining 15 patients are alive without evidence of disease. Four patients experienced acute grade 3 toxicities: dermatitis (N = 3) and oral mucositis (N = 1). One patient developed a chronic grade 4 optic nerve disorder. There were no grade 5 toxicities. Intensity-modulated proton therapy is a feasible option for patients with ACC of the head and neck in the postoperative setting. Robust treatment planning and plan analysis can be performed such that uncertainties and tissue heterogeneities do not appear to limit safe and effective IMPT delivery. Safety and efficacy appear comparable to those of other types of radiation therapy, but further follow-up of clinical outcomes is needed.